Understanding how CD38 affects NAD metabolism in scleroderma
CD38 modulation of NAD metabolism driving scleroderma pathogenesis
This study is looking at how a protein called CD38 affects a substance in the body that helps with energy and may play a role in the development of scleroderma, a condition that causes hardening and damage to organs, and it aims to find new treatment options by working with patient samples and animal models.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10913581 on NIH RePORTER |
What this research studies
This research investigates the role of CD38 and its impact on NAD metabolism in the development of scleroderma, a condition that causes fibrosis and damage to multiple organs. The study aims to explore how dysregulation of NAD and nicotinamide metabolism contributes to the disease's progression. By examining patient biopsies and using animal models, the researchers will assess the potential of targeting CD38 and related enzymes as a new therapeutic approach. Patients may be involved in providing biopsies or participating in related clinical assessments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic sclerosis (scleroderma) who are experiencing fibrosis-related complications.
Not a fit: Patients with other forms of fibrosis not related to scleroderma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target the underlying mechanisms of scleroderma, potentially improving patient outcomes.
How similar studies have performed: While the approach of targeting NAD metabolism in scleroderma is novel, preliminary findings suggest that similar strategies have shown promise in other fibrotic conditions.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Varga, John — University of Michigan at Ann Arbor
- Study coordinator: Varga, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.